Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins

European Journal of Cancer

Volumn 81, Issue , 2017, Pages 203-205

  Spänkuch, Iris ^a   Gassenmaier, Maximilian ^a   Tampouri, Ioanna ^a   Noor, Seema ^a   Forschner, Andrea ^a   Garbe, Claus ^a   Amaral, Teresa ^a,b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Portuguese Air Force Health Direction   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; INSULIN; IPILIMUMAB; LEVOTHYROXINE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; NIVOLUMAB; PREDNISOLONE; THYMOCYTE ANTIBODY; ANTINEOPLASTIC AGENT; CORTICOSTEROID; IMMUNOGLOBULIN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; AUTOIMMUNE HEPATITIS; AUTOIMMUNE THYROIDITIS; AXILLARY LYMPH NODE; CANCER ADJUVANT THERAPY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; FEMALE; GENE MUTATION; HUMAN; IMMUNOTHERAPY; LETTER; LUNG METASTASIS; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; METASTATIC BREAST CANCER; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY; CASE REPORT; HEPATITIS; IMMUNOLOGY; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SKIN TUMOR; THYMOCYTE; TOXIC HEPATITIS;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMICAL AND DRUG INDUCED LIVER INJURY; FEMALE; HEPATITIS; HUMANS; IMMUNOGLOBULINS; IMMUNOTHERAPY; IPILIMUMAB; MELANOMA; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SKIN NEOPLASMS; THYMOCYTES;

EID: 85020935367     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.05.018     Document Type: Letter

References (7)

1. Wolchok, Jedd D., Chiarion-Sileni, Vanna, Gonzalez, Rene, Rutkowski, Piotr, Grob, Jean Jacques, Cowey, Charles Lance, et al. Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). J Clin Oncol, 33, 2015 (suppl; abstr LBA1). 2015.
2. Postow, M.A., Chesney, J., Pavlick, A.C., Robert, C., Grossmann, K., McDermott, D., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372 (2015), 2006–2017.
3. YERVOY, A.R., Management guide. 2015 Last access 11th April 2017 http://wwwhcpyervoycom/.
4. Opdivo, A.R., Management guide. 2017 Last access 11th April 2017 http://wwwopdivoyervoyhcpcom/servlet/servletFileDownload?file=00Pi000000SRPWfEAP.
5. Weber, J.S., Kähler, K.C., Hauschild, A., Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30 (2012), 2691–2697.
6. National Cancer Institute, Common terminology criteria for adverse events (CTCAE) v.4.03. 2009 Last access 11th April 2017 http://evsncinihgov/.
7. Chmiel, K.D., Suan, D., Liddle, C., Nankivell, B., Ibrahim, R., Bautista, C., et al. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol 29 (2011), e237–e240.